Identification of multiple sources of charge heterogeneity in a recombinant antibody

被引:413
作者
Harris, RJ
Kabakoff, B
Macchi, FD
Shen, FJ
Kwong, M
Andya, JD
Shire, SJ
Bjork, N
Totpal, K
Chen, AB
机构
[1] Genentech Inc, Dept Analyt Chem, S San Francisco, CA 94080 USA
[2] Genentech Inc, Qual Control Dept, S San Francisco, CA 94080 USA
[3] Genentech Inc, Pharmaceut Res & Dev Dept, S San Francisco, CA 94080 USA
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 752卷 / 02期
关键词
charge heterogeneity; peptide mapping; recombinant antibody;
D O I
10.1016/S0378-4347(00)00548-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Seven forms of a therapeutic recombinant antibody that binds to the her2/neu gene product were resolved by cation-exchange chromatography. Structural differences were assigned by peptide mapping and HIC after papain digestion. Deamidation of light chain asparagine 30 to aspartate in one or both light chains is responsible for two acidic forms. A low potency form is due to isomerization of heavy chain aspartate 102: the Asp102 succinimide is also present in a basic peak fraction. Forms with both Asn30 deamidation and Asp102 isomerization modifications were isolated. Deamidation of heavy chain Asn55 to isoaspartate was also detected. Isoelectric focusing in a polyacrylamide gel was used to verify the assignments. All modifications were found in complementarity determining regions. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:233 / 245
页数:13
相关论文
共 35 条
  • [1] MONITORING OF IGG ANTIBODY THERMAL-STABILITY BY MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY AND MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS-SPECTROMETRY
    ALEXANDER, AJ
    HUGHES, DE
    [J]. ANALYTICAL CHEMISTRY, 1995, 67 (20) : 3626 - 3632
  • [2] Amphlett G, 1996, Pharm Biotechnol, V9, P1
  • [3] SEQUENCE-SPECIFIC DEAMIDATION - ISOLATION AND BIOCHEMICAL-CHARACTERIZATION OF SUCCINIMIDE INTERMEDIATES OF RECOMBINANT HIRUDIN
    BISCHOFF, R
    LEPAGE, P
    JAQUINOD, M
    CAUET, G
    ACKERKLEIN, M
    CLESSE, D
    LAPORTE, M
    BAYOL, A
    VANDORSSELAER, A
    ROITSCH, C
    [J]. BIOCHEMISTRY, 1993, 32 (02) : 725 - 734
  • [4] Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity
    Cacia, J
    Keck, R
    Presta, LG
    Frenz, J
    [J]. BIOCHEMISTRY, 1996, 35 (06) : 1897 - 1903
  • [5] HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY
    CARTER, P
    PRESTA, L
    GORMAN, CM
    RIDGWAY, JBB
    HENNER, D
    WONG, WLT
    ROWLAND, AM
    KOTTS, C
    CARVER, ME
    SHEPARD, HM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) : 4285 - 4289
  • [6] Herceptin®:: Breaking new ground
    Cohen, RL
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (01) : 1 - 4
  • [7] EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P237
  • [8] X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM 3 VARIANTS OF HUMANIZED ANTI-P185HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
    EIGENBROT, C
    RANDAL, M
    PRESTA, L
    CARTER, P
    KOSSIAKOFF, AA
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1993, 229 (04) : 969 - 995
  • [9] FENDLY BM, 1990, CANCER RES, V50, P1550
  • [10] GEIGER T, 1987, J BIOL CHEM, V262, P785